Technical Articles: Reagent Chemistry, Synthesis & Bioscience Guides

Imatinib (STI571) FAQs: Mechanism, Use & Storage

Imatinib (STI571) is a potent, selective small-molecule inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases, widely used as a research tool compound in oncology and cell-signaling studies.

Chemical Name
4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Primary Targets
BCR-ABL, c-Kit, PDGFR-α, PDGFR-β
Molecular Weight
493.60 g/mol
Recommended Storage
-20 °C, away from light and moisture
Selleck Catalog Number
S2475
Research Application
In vitro kinase inhibition, apoptosis assays, CML and GIST cell-line studies

What Is Imatinib (STI571) and How Does It Work?

Imatinib (STI571) (I407799) is a small-molecule tyrosine kinase inhibitor (TKI) that competitively occupies the ATP-binding pocket of BCR-ABL, c-Kit, and PDGFR kinases, stabilizing the inactive (DFG-out) conformation and preventing substrate phosphorylation. By blocking these oncogenic kinases, imatinib effectively suppresses downstream proliferative and anti-apoptotic signaling pathways including RAS/MAPK and PI3K/AKT. In research settings it is a standard positive-control compound for BCR-ABL-driven signaling studies in chronic myeloid leukemia (CML) models and for c-Kit inhibition in gastrointestinal stromal tumor (GIST) cell lines.

Solubility and Reconstitution Guidelines

Imatinib (STI571) is freely soluble in DMSO (typically ≥50 mg/mL) and soluble in water at acidic pH. For aqueous-based assays, prepare a concentrated stock in DMSO and dilute into buffer or cell culture medium; ensure the final DMSO concentration does not exceed 0.1% (v/v) to avoid cytotoxicity artifacts. Avoid repeated freeze-thaw cycles: prepare single-use aliquots from the stock solution. If a water-based stock is required, dissolve in PBS or cell culture medium at mildly acidic pH and use immediately. Always verify solubility empirically for each new lot and assay matrix, as formulation and salt form can influence solubility.

Storage, Stability, and Handling

Store Imatinib (STI571) as a solid at -20 °C in a desiccated, light-protected environment. Under these conditions the compound is expected to be stable for at least two years. DMSO stock solutions should be stored at -20 °C in tightly sealed vials; avoid exposure to moisture, which can cause hydrolysis. Allow the vial to equilibrate to room temperature before opening to prevent condensation. Wear appropriate personal protective equipment (PPE) including gloves and lab coat when handling; although this is a research reagent, imatinib is a pharmacologically active compound and routine laboratory safety precautions apply.

Research Applications and Typical Working Concentrations

Imatinib (STI571) is widely employed in the following research contexts:

  • BCR-ABL inhibition assays: Published IC50 values for BCR-ABL inhibition are in the low nanomolar range; typical cell-based working concentrations range from 0.1 µM to 10 µM depending on the cell line and endpoint measured.
  • c-Kit and PDGFR studies: Imatinib inhibits c-Kit and PDGFR with IC50 values also reported in the nanomolar range, making it suitable for GIST and stromal-tumor model systems.
  • Apoptosis and cell-cycle assays: Commonly used as a positive control in caspase-activation, annexin-V, and cell-cycle arrest experiments in CML cell lines such as K562.
  • Combination studies: Frequently paired with second-generation TKIs or chemotherapeutic agents to investigate synergistic or additive effects in kinase-driven cancers.

Exact working concentrations should be optimized empirically for each experimental system.

Quality, Purity, and Regulatory Notes

Imatinib (STI571) (SKU I407799) is offered as a research-grade reagent cross-referenced to Selleck catalog number S2475. Purity is typically ≥98% by HPLC; a Certificate of Analysis (CoA) with lot-specific purity, NMR, and MS data is available upon request. This product is intended solely for in vitro research and laboratory use; it is not approved, tested, or suitable for human or veterinary diagnostic or therapeutic use. Researchers should consult current institutional biosafety and chemical-hygiene guidelines before use.

Frequently asked questions

What is the mechanism of action of Imatinib (STI571)?

Imatinib (STI571) competitively binds the ATP-binding site of BCR-ABL, c-Kit, and PDGFR tyrosine kinases, locking them in an inactive conformation and preventing substrate phosphorylation. This blocks downstream RAS/MAPK and PI3K/AKT signaling that drives tumor-cell proliferation and survival. It is classified as a Type II kinase inhibitor due to its preference for the DFG-out inactive conformation.

What solvent should I use to dissolve Imatinib (STI571) for cell-based assays?

DMSO is the recommended primary solvent; Imatinib (STI571) is typically soluble in DMSO at ≥50 mg/mL. Dilute the DMSO stock into cell culture medium immediately before use and ensure the final DMSO concentration is ≤0.1% (v/v) to minimize cytotoxic effects on cells. If aqueous solubility is needed, dissolve in mildly acidic aqueous buffer and use promptly.

How should Imatinib (STI571) be stored to maintain stability?

Store Imatinib (STI571) as a solid at -20 °C in a dry, light-protected environment for long-term stability. DMSO stock solutions should also be kept at -20 °C in sealed, desiccated vials and protected from moisture. Prepare single-use aliquots to avoid repeated freeze-thaw cycles, which can degrade the compound over time.

What cell lines are commonly used to study the activity of Imatinib (STI571)?

The BCR-ABL-positive K562 cell line (derived from a CML patient) is the most widely used model for evaluating Imatinib (STI571) activity in vitro. GIST cell lines expressing activating c-Kit mutations are frequently used to assess imatinib's c-Kit inhibitory effects. Imatinib-resistant lines such as K562-R carrying the T315I gatekeeper mutation serve as controls for resistance mechanism studies.

Is Imatinib (STI571) from Aladdin Scientific suitable for animal studies?

Imatinib (STI571) (I407799) is supplied as a research-grade reagent intended for in vitro laboratory use. While many published studies have used imatinib in rodent xenograft and pharmacological models, researchers intending in vivo use must independently validate the compound's suitability, formulation, and dosing for their specific animal model and comply with all relevant institutional and regulatory requirements.

References

  1. Druker BJ, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. 1996.
  2. Capdeville R, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews Drug Discovery. 2002.
  3. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.

Categories: Technical Articles: Reagent Chemistry, Synthesis & Bioscience Guides

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.

Cite this article

Aladdin Scientific. "Imatinib (STI571) FAQs: Mechanism, Use & Storage" Aladdin Knowledge Base, updated 20/11/2026. https://www.aladdinsci.com/us_pt/faqs/imatinib-sti571-faq-en.html
Was this article helpful? Yes No 1 out of 1 found this helpful

Deseja que lhe enviemos uma mensagem quando tivermos descontos disponíveis?

Lembrar-me mais tarde

Obrigado! Por favor, verifique a sua caixa de entrada de e-mail para confirmar.

Ops! As notificações estão desativadas.